New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...

Scientists have discovered a naturally occurring molecule that aids appetite control and weight loss so well, it may compete ...

Jab for joy? A landmark study of nearly 30,000 patients found that the use of GLP-1 medications, which include Wegovy and ...

Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...

Four companies have applied to Health Canada to sell copies of Ozempic after its market exclusivity expires on Jan. 4, 2026 ...